La Jolla Pharmaceutical Co. Files SEC Form 4 Statement

Strategic Insights -

La Jolla Pharmaceutical Co, a US-based pharmaceutical company, has submitted a statement of ownership regarding its security on Form 4 to the Securities and Exchange Commission (SEC). This filing, dated December 12, 2014, is a requirement for every director, officer, or owner of more than ten percent of a class of equity securities registered under Section 12 of the '34 Act. The statement contains information on the reporting person's relationship to the company and on purchases and sales of such equity securities.

Key Takeaways:

  • La Jolla Pharmaceutical Co. submitted a Form 4 statement to the SEC on December 12, 2014.
  • The company is required to file this statement due to its ownership in equity securities registered under Section 12 of the '34 Act.
  • The statement includes information on the reporting person's relationship to the company and on purchases and sales of equity securities.
  • The SIC code for La Jolla Pharmaceutical Co. is 2836, Biological Products, (No Diagnostic Substances).
  • The company's contact information is 4660 LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122, 858-207-4264.
  • The SEC filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.

Statistics:

  • 1 document was filed with the SEC Form 4.
  • The SEC file number is 0000920465-14-000129.
  • The initial filing is on Form 3, and changes are reported on Form 4.
  • The Annual Statement of beneficial ownership of securities is on Form 5.
  • 100% of the required information was submitted in the Form 4 filing.

Sources:

  • U.S. Securities and Exchange Commission filing by La Jolla Pharmaceutical Co (December 12, 2014).
  • News article from NewsRx regarding La Jolla Pharmaceutical Co.'s SEC filing.